268 related articles for article (PubMed ID: 30715411)
1. Prognostic index score predicts outcome of patients with Stage I non-small cell lung cancer after stereotactic body radiation therapy.
Shi S; Ye L; Zhao Q; Hu Y; Huang Y; Chen G; Zeng Z; He J
Jpn J Clin Oncol; 2019 Apr; 49(4):367-372. PubMed ID: 30715411
[TBL] [Abstract][Full Text] [Related]
2. Response criteria in solid tumors (PERCIST/RECIST) and SUV
Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment
Satoh Y; Motosugi U; Saito A; Omiya Y; Onishi H
Technol Cancer Res Treat; 2018 Jan; 17():1533033818794934. PubMed ID: 30222060
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
Stahl JM; Ross R; Harder EM; Mancini BR; Soulos PR; Finkelstein SE; Shafman TD; Dosoretz AP; Evans SB; Husain ZA; Yu JB; Gross CP; Decker RH
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1011-1020. PubMed ID: 27869080
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment Immune Parameters Predict for Overall Survival and Toxicity in Early-Stage Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
Shaverdian N; Veruttipong D; Wang J; Schaue D; Kupelian P; Lee P
Clin Lung Cancer; 2016 Jan; 17(1):39-46. PubMed ID: 26372098
[TBL] [Abstract][Full Text] [Related]
6. FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer.
Kohutek ZA; Wu AJ; Zhang Z; Foster A; Din SU; Yorke ED; Downey R; Rosenzweig KE; Weber WA; Rimner A
Lung Cancer; 2015 Aug; 89(2):115-20. PubMed ID: 26078260
[TBL] [Abstract][Full Text] [Related]
7. Prior Treatment for Non-small Cell Lung Cancer Is Associated With Improved Survival in Patients who Undergo Definitive Stereotactic Body Radiation Therapy for a Subsequent Lung Malignancy: A Retrospective Multivariate and Matched Pair Analysis.
Farrugia MK; Jun Ma S; Hennon MW; Nwogu CE; Dexter EU; Picone AL; Demmy TL; Gomez-Suescun JA; Fung-Kee-Fung S; Yendamuri SS; Singh AK
Am J Clin Oncol; 2021 Jan; 44(1):18-23. PubMed ID: 33264123
[TBL] [Abstract][Full Text] [Related]
8. Prognostic utility of blood inflammation biomarkers before and after treatment on the survival of patients with locally advanced non-small cell lung cancer undergoing stereotactic body radiotherapy.
Fang F; Jia Z; Xie H; Cao Y; Zhu X; Yang XY; Guo X; Zhang H
Clin Respir J; 2024 May; 18(5):e13749. PubMed ID: 38685745
[TBL] [Abstract][Full Text] [Related]
9. Lung stereotactic body radiation therapy for elderly patients aged ≥ 80 years with pathologically proven early-stage non-small cell lung cancer: a retrospective cohort study.
Watanabe K; Katsui K; Sugiyama S; Yoshio K; Kuroda M; Hiraki T; Kiura K; Maeda Y; Toyooka S; Kanazawa S
Radiat Oncol; 2021 Feb; 16(1):39. PubMed ID: 33622369
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer.
Cannon NA; Meyer J; Iyengar P; Ahn C; Westover KD; Choy H; Timmerman R
J Thorac Oncol; 2015 Feb; 10(2):280-5. PubMed ID: 25299234
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic value of pretreatment neutrophil-to-lymphocyte ratio (NLR) in locally advanced non-small cell lung cancer patients treated with thoracic radiation].
Dong X; Zhou ZM; Bi N; Wang JB; Ran JT; Hui ZG; Liang J; Feng QF; Chen DF; Xiao ZF; Lyu JM; Wang XZ; Wang X; Zhang T; Deng L; Wang WQ; Wang LH
Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):446-451. PubMed ID: 29936771
[No Abstract] [Full Text] [Related]
12. Metabolic tumor volume on FDG-PET/CT is a possible prognostic factor for Stage I lung cancer patients treated with stereotactic body radiation therapy: a retrospective clinical study.
Takahashi N; Yamamoto T; Matsushita H; Sugawara T; Kubozono M; Umezawa R; Ishikawa Y; Kozumi M; Katagiri Y; Tasaka S; Takeda K; Takeda K; Dobashi S; Jingu K
J Radiat Res; 2016 Nov; 57(6):655-661. PubMed ID: 27422935
[TBL] [Abstract][Full Text] [Related]
13. Prognositc significance of SUV
Dong M; Liu J; Sun X; Xing L
J Med Imaging Radiat Oncol; 2017 Oct; 61(5):652-659. PubMed ID: 28266166
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic body radiation therapy versus conventionally fractionated radiation therapy for early stage non-small cell lung cancer.
Haque W; Verma V; Polamraju P; Farach A; Butler EB; Teh BS
Radiother Oncol; 2018 Nov; 129(2):264-269. PubMed ID: 30031630
[TBL] [Abstract][Full Text] [Related]
15. Nomograms for predicting disease progression in patients of Stage I non-small cell lung cancer treated with stereotactic body radiotherapy.
Ye L; Shi S; Zeng Z; Huang Y; Hu Y; He J
Jpn J Clin Oncol; 2018 Feb; 48(2):160-166. PubMed ID: 29253245
[TBL] [Abstract][Full Text] [Related]
16. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
[TBL] [Abstract][Full Text] [Related]
17. Use of frailty to predict survival in elderly patients with early stage non-small-cell lung cancer treated with stereotactic body radiation therapy.
Franco I; Chen YH; Chipidza F; Agrawal V; Romano J; Baldini E; Chen A; Colson Y; Hou Y; Kozono D; Wee J; Mak R
J Geriatr Oncol; 2018 Mar; 9(2):130-137. PubMed ID: 28941581
[TBL] [Abstract][Full Text] [Related]
18. Location Matters: Stage I Non-Small-cell Carcinomas of the Lower Lobes Treated With Stereotactic Body Radiation Therapy Are Associated With Poor Outcomes.
Shaverdian N; Veruttipong D; Wang J; Kupelian P; Steinberg M; Lee P
Clin Lung Cancer; 2017 Mar; 18(2):e137-e142. PubMed ID: 27908620
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment Modified Glasgow Prognostic Score Predicts Clinical Outcomes After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer.
Kishi T; Matsuo Y; Ueki N; Iizuka Y; Nakamura A; Sakanaka K; Mizowaki T; Hiraoka M
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(3):619-26. PubMed ID: 26068494
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.
Vu CC; Matthews R; Kim B; Franceschi D; Bilfinger TV; Moore WH
Nucl Med Commun; 2013 Oct; 34(10):959-63. PubMed ID: 23921784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
